We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

5 hedge funds and large institutions have $443K invested in Biotech Acquisition Company Unit in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 10 → 5 (-5)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

85% less capital invested

Capital invested by funds: $2.96M → $443K (-$2.52M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
5
Holders Change
-5
Holders Change %
-50%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
3
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$1.02K
2
CS
Clear Street
New York
+$69

Top Sellers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
-$889K
2
WCMNY
Westchester Capital Management (New York)
New York
-$494K
3
Janus Henderson Group
Janus Henderson Group
-$413K
4
Walleye Capital
Walleye Capital
New York
-$369K
5
LCM
Landscape Capital Management
New Jersey
-$218K

BIOTU Hedge Fund Activity: Q2 2022 in Review

5 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q2 2022, worth a combined $443K — down 85% from $2.96M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BIOTU and 2 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 0 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.02K. The largest seller was HRT Financial, exiting entirely with an estimated $889K sold.

  • 5 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q2 2022, down from 10 in Q1 2022.
  • Funds reported $443K of Biotech Acquisition Company Unit stock for Q2 2022, down 85% quarter-over-quarter.
  • 2 funds opened new Biotech Acquisition Company Unit positions in Q2 2022 and 7 closed out, a net change of -5 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q2 2022 was Tower Research Capital (TRC), an estimated $1.02K added.
  • The largest Biotech Acquisition Company Unit seller in Q2 2022 was HRT Financial, an estimated $889K sold.

Based on aggregated 13F filings for Q2 2022.